Pharma BD Deal Intelligence
Partially achieved: AstraZeneca's $1.3B (£702M) 2006 buy of Cambridge Antibody Technology handed it the phage-display science behind tralokinumab (Adtralza/Adbry), but AZ recouped over half the price weeks later by flipping CAT's Humira royalty to Royalty Pharma for $700M, not through pipeline payoff.
CAT's phage-display science became the backbone of AstraZeneca's biologics R&D, but the deal's own economics were only ever rescued by flipping CAT's pre-existing Humira royalty for $700M weeks after close — the direct pipeline payoff (tralokinumab, and indirectly benralizumab via the later MedImmune deal) came a decade-plus later and mostly benefited licensees/AZ's broader MedImmune-era business, not a clean CAT-specific ROI.
Full analysis, sources & comparables →$1.3B price reflected CAT's status as 'jewel in the crown' of UK biotech, with proven Humira economics and clinical pipeline of four mAbs.
CAT's phage-display platform, which produced Humira and belimumab, was merged with MedImmune (acquired 2007) to form AZ's biologics R&D division - validating…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Antibody phage display platform; GBP 702M total; AZN already held 19.2%
CAT's phage-display science became the backbone of AstraZeneca's biologics R&D, but the deal's own economics were only ever rescued by flipping CAT's pre-existing Humira royalty for $700M weeks after close — the direct pipeline payoff (tralokinumab, and indirectly benralizumab via the later MedImmune deal) came a decade-plus later and mostly benefited licensees/AZ's broader MedImmune-era business, not a clean CAT-specific ROI.
Assessment window: 15yr post-close.
$1.4B Humira (CAT-discovered) 2005 global sales (proof point at deal time)
Cambridge Antibody Technology (CAT) was a UK biotech founded in 1989 that pioneered phage display for fully human monoclonal antibody discovery. Its platform yielded adalimumab (Humira), the world's first fully human mAb and eventual best-selling drug, plus belimumab (Benlysta) and a clinical pipeline targeting inflammation, oncology, and respiratory disease.
By 2006, monoclonal antibody platforms were the strategic prize of pharma M&A. Competing antibody discovery technologies included Medarex's HuMAb-Mouse and Abgenix's XenoMouse (transgenic platforms), Genmab's UniBody, and Regeneron's VelocImmune (in development). AstraZeneca, weak in biologics following Galida's Phase 3 failure, paid £702M (~$1.3B) for the ~81% of CAT it didn't already own (it held ~19.2% from a 2004 collaboration) - a 67% premium. CAT brought four clinical-stage mAbs (CAT-3888 for hairy cell leukemia, CAT-354 anti-IL-13 for asthma, plus mavrilimumab/CAT-8015 derivatives) plus economic interest in Humira (then ~$1.4B 2005 sales, fastest-growing biologic) and Benlysta royalty rights via the GSK partnership. Strategically, AZ stated the deal would 'create a major R&D capability to deliver biological therapeutics' and target 25% biologics share of pipeline by 2010. The transaction set up AZ's subsequent $15.6B MedImmune acquisition (2007), which combined with CAT formed the foundation of today's MedImmune/AstraZeneca biologics franchise. Industry context: Merck simultaneously paid $480M for GlycoFi+Abmaxis - signaling broad pharma rush into antibody platforms.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Cambridge Antibody Technology Group plc (this deal) | 2006 | $1.3B | 67 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2006 deals · AstraZeneca PLC deals